Aminoglycosides Market Report 2026

Aminoglycosides Market Overview

• Aminoglycosides market size has reached to $1.91 billion in 2025 • Expected to grow to $2.56 billion in 2030 at a compound annual growth rate (CAGR) of 6% • Growth Driver: Aminoglycosides Market Surges Amidst Escalating Animal Disease Outbreaks • Market Trend: Process Innovation Emerges As A Pivotal Trend In The Aminoglycosides Market • Asia-Pacific was the largest region in 2025 and North America is the fastest growing region.

What Is Covered Under Aminoglycosides Market?

Aminoglycoside is a class of antibiotics that inhibits protein synthesis. These are used in the treatment of aerobic gram-negative bacilli infections of the abdomen and urinary tract, as well as bacteremia and endocarditis The main products of aminoglycosides are neomycin, tobramycin, gentamicin, amikacin, paromomycin, streptomycin, kanamycin and others. The neomycin are used to prevent bacterial infection in the intestines. Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. The route of administration of aminiglycosides includes injectables (parenteral), feed, intra-mammary, topical and oral and applied in veterinary, skin infection, respiratory diseases, UTI & pelvic diseases and other diseases.

What Is The Aminoglycosides Market Growth Forecast?

The aminoglycosides market size is expected to see strong growth in the next few years. It will grow to $2.56 billion in 2030 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to increased r&d in targeted aminoglycoside therapies, rising awareness of antibiotic resistance, adoption of advanced drug delivery systems, expansion of veterinary healthcare market, growth in personalized medicine applications. Major trends in the forecast period include rising prevalence of gram-negative infections, increased veterinary use of aminoglycosides, development of novel aminoglycoside derivatives, shift towards injectable and targeted formulations, expansion of ophthalmic and inhalation applications.

Global Aminoglycosides Market Segmentation

1) By Product: Neomycin, Tobramycin, Gentamicin, Amikacin, Paromomycin, Streptomycin, Kanamycin, Other Products 2) By Route Of Administration: Injectables (Parenteral), Feed, Intra-Mammary, Topical, Oral 3) By Application: Veterinary, Skin Infection, Respiratory Diseases, UTI And Pelvic Diseases, Other Diseases

What Are The Drivers Of The Aminoglycosides Market?

The rising incidences of animal disease outbreaks are a major driver expected to propel the growth of the aminoglycosides market going forward. Animal disease is an impairment of the normal state of an animal that interrupts or modifies its vital functions. Aminoglycosides such as amikacin and gentamicin are the most commonly used in veterinary medicine. For instance, in July 2025, according to GOV.UK, a UK-based government agency reported that the lab-confirmed cases of leptospirosis in England increased from 70 in 2023 to 102 in 2024, representing a 45.7% rise. Further, there were 890 cases of pasteurellosis reported in 2024, compared with 815 in 2023. Therefore, the rising incidences of animal disease outbreaks will continue to drive the aminoglycosides industry. The increase in pet ownership is expected to propel the growth of the aminoglycosides market going forward. Pet ownership refers to the act of keeping and caring for animals, commonly referred to as pets, within one's home or living space. Increased pet ownership enhances the aminoglycoside market by creating a larger customer base, fostering a culture of preventive healthcare for pets, and encouraging investments in veterinary pharmaceuticals to address the diverse health needs of companion animals. For instance, in March 2023, according to Improve International, a US-based veterinary educational resource, there are 38 million pets in 16.2 million UK households, or around 57% of all households. Therefore, the increase in pet ownership is driving the growth of the aminoglycosides industry.

Key Players In The Global Aminoglycosides Market

Major companies operating in the aminoglycosides market are Kremoint Pharma Pvt. Ltd., Vega Pharma Ltd., Jiangxi Bolai Pharmacy Co. Ltd., Xian Wison Biological Technology Co. Ltd., Hangzhou Uniwise International Co. Ltd., HuvePharma Inc., Yi Chang Veterinary Medicine Factory, Medson Pharmaceuticals, Medico Remedies Pvt. Ltd., Cipla Limited, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Zoetis Inc., Novartis AG, Johnson & Johnson Inc., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Zydus Lifescience Limited, Lupin Limited, Aurobindo Pharma Limited, Fresenius Kabi AG, Aspen Pharmacare Holdings Limited, Mylan N.V., Sanofi SA, Wyeth Pharmaceuticals Inc., Zhejiang Hisun Pharmaceutical Co. Ltd., GlaxoSmithKline plc, Allergan PLC, Bristol Myers Squibb Company

Global Aminoglycosides Market Trends and Insights

Major companies operating in the aminoglycosides market are focusing on developing innovative solutions, such as advanced manufacturing and formulation process improvements, to meet the rising demand for high-efficacy, next-generation antibiotics capable of treating resistant bacterial infections. These process innovations enhance purity, stability, and therapeutic efficiency compared with traditional aminoglycoside production methods. For instance, in February 2024, Cipla Limited, an India-based pharmaceutical company, received approval from the Central Drugs Standard Control Organization (CDSCO) for ZEMDRI (plazomicin), an intravenous aminoglycoside antibiotic, in India. This antibiotic is specifically indicated for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis.

Regional Insights

Asia-Pacific was the largest region in the aminoglycosides market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Aminoglycosides Market?

The aminoglycosides market consists of sales of plazomicin and netilmicin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Aminoglycosides Market Report 2026?

The aminoglycosides market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the aminoglycosides industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.